XADAGO
Peaksafinamide mesylate
NDAORALTABLET
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XADAGO (safinamide mesylate) is an oral monoamine oxidase type B inhibitor approved for Parkinson's disease. It is used as an adjunctive treatment to levodopa/carbidopa in patients experiencing motor fluctuations. The drug works by inhibiting MAO-B enzyme activity, thereby increasing dopamine levels in the brain.
$0.003BPart D
Peak4.9 years to LOEProduct is at peak lifecycle with modest Medicare spending ($3M in 2023) and limited claims volume, indicating a niche market with stable but constrained commercial opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
Started Nov 2017
164 enrolled
Idiopathic Parkinson Disease
Why This Matters for Your Career
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.